Loading...
XNAS
PRPO
Market cap47mUSD
Jul 09, Last price  
26.48USD
1D
1.38%
1Q
-2.83%
Jan 2017
-68.94%
IPO
-99.60%
Name

Precipio Inc

Chart & Performance

D1W1MN
XNAS:PRPO chart
P/E
—
P/S
1.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.27%
Rev. gr., 5y
31.60%
Revenues
24m
+50.64%
23,415,00023,176,00023,993,00022,023,00020,048,00031,971,00031,480,00027,544,00027,083,0001,653,0001,557,0001,723,0002,864,0003,127,0006,092,0008,849,0009,412,00015,197,00015,965,00024,049,000
Net income
-363k
L-91.54%
-3,431,000-2,107,000-495,000-1,920,000-3,134,000-9,782,000-8,327,000-15,987,000-13,942,000-32,954,000-7,616,000-20,694,000-15,694,000-13,243,000-10,625,000-8,550,000-12,203,000-5,853,000-4,290,000-363,000
CFO
685k
+56.04%
-1,212,000-2,939,000-413,0001,267,000-1,718,000220,000-10,204,000-8,473,000-13,702,000-12,378,000-3,550,000-6,690,000-6,754,000-9,141,000-7,434,000-6,577,000-7,721,000-3,559,000439,000685,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
URL
http://www.precipiodx.com/
IPO date
Jul 18, 2000
Employees
53
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT